Neogen Chemicals: Promoter Gifts 62.8 Lakh Shares to Family Trusts
Promoter Haridas Thakarshi Kanani gifted 62,80,500 equity shares of Neogen Chemicals on December 31, 2025. The shares were transferred via off-market transactions to Haridas Kanani Family Trust (52,76,500 shares) and H T Kanani Family Trust (5,02,000 shares). This transaction represents approximately 23.72% of the paid-up capital.
While the transaction is a gift and an inter-se transfer within the promoter group, the significant number of shares transferred (over 62 lakh shares, representing a substantial portion of paid-up capital) could lead to a change in the direct holding pattern and potentially influence market perception.
The transaction involves a gift of shares from a promoter to family trusts, which is an internal restructuring within the promoter group and does not inherently indicate a positive or negative change in the company's business or financial performance.
Neogen Chemicals Limited has announced a significant transaction involving its Promoter and Chairman Emeritus, Haridas Thakarshi Kanani. On December 31, 2025, Mr. Kanani gifted a total of 62,80,500 equity shares of the company through off-market transactions.
These shares, representing approximately 23.72% of the company's paid-up capital, were transferred to two family trusts: Haridas Kanani Family Trust and H T Kanani Family Trust. The disclosure was made pursuant to Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The transaction falls under inter-se transfer within the promoter group.
Haridas Kanani Family Trust acquired 52,76,500 equity shares, while H T Kanani Family Trust acquired 5,02,000 equity shares. Both trusts are to be classified as Promoter shareholders post-acquisition, following a SEBI Exemption Order dated December 30, 2025. The market price as of December 30, 2025, was ₹1,163.20 per share.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.